Media
AI Drug Discovery Breakthroughs Move From Promise to Proof in 2025
AI Drug Discovery in 2025: In silico Medicine’s Pipeline Moves From Promise to Proof
Artificial intelligence (AI) in drug discovery has moved beyond theory. In 2025, the drug manufacturing companies have moved several AI-originated molecules past critical milestones. It has secured regulatory designations, dosed patients in multi-country studies, and even published results in high-impact journals.
The moment is reminiscent of other paradigm shifts in drug development, such as the debut of monoclonal antibodies in the 1990s or the emergence of checkpoint inhibitors in the early 2010s. The focus has now shifted from “Can AI create viable drugs?” to “How soon can these AI-created drugs improve patient care?”
The Shift: From Algorithms to Patients
Normally, finding a new drug can take 4–6 years before it even reaches testing in humans. But thanks to AI technology, this process can be much faster. For example, the drug candidate ISM5411 went from an idea to a ready-for-preclinical testing stage in just 12 months, while keeping a precise, targeted design.
This method focuses on hitting the right target from the start, rather than exploring randomly. Table 1: AI Drug Pipeline 2025 below highlights successful examples of this approach.
Table 1: AI Drug Pipeline 2025
| Candidate | Target | Indication | 2025 Milestone | Next Step | Regulatory Status | References |
|---|---|---|---|---|---|---|
| Rentosertib (ISM001-055) | TNIK | Idiopathic Pulmonary Fibrosis | Phase IIa (Nature Medicine): +98.4 mL FVC gain at 60 mg | Launch Phase IIb/III late 2025 | Orphan Drug (FDA) | [1],[2],[6],[8] |
| ISM5411 | PHD1/2 | Ulcerative Colitis | Phase I: safe, gut-restricted PK profile | Start Phase II H2 2025 | — | [3] |
| ISM6331 | Pan-TEAD | Mesothelioma / Hippo-pathway tumours | First patient dosed in global Phase I | Complete dose escalation; biomarker-enriched cohorts | Orphan Drug (FDA) | [4],[7] |
| ISM3412 | MAT2A | MTAP-deleted cancers | First patient dosed; no DLTs in initial cohort | Establish Phase II dose; biomarker strategy | — | [5] |
| ISM5939 | ENPP1 | Solid tumours (immuno-oncology) | IND cleared (late 2024) | Begin Phase I 2025–26 | — | [9] |
Market and Development Outlook
As these AI-designed drugs progress, their market impact will hinge on:
- Clinical Efficacy: Sustained Forced vital capacity (FVC) improvements for rentosertib, endoscopic healing for ISM5411, and measurable tumour shrinkage for oncology candidates.
- Regulatory Engagement: Early orphan drug designations suggest a strategy aligned with accelerated approval pathways.
- Pipeline Synergy: Drug candidates like ISM3412 and ISM5939 could combine with other targeted agents or immunotherapies, broadening utility.
- Investor Confidence: Peer-reviewed publications and multinational trial footprints bolster credibility and funding potential.
Preparing for the Next Phase
To capitalise on its 2025 progress, In silico Medicine is expected to prioritise:
- Scaling Clinical Operations: Rapid site activation for pivotal trials.
- Biomarker Integration: Ensuring precision enrolment in oncology studies.
- Global Regulatory Strategy: Coordinating submissions in multiple major markets.
- Partnerships: Leveraging co-development or licensing deals to expand reach.
- Portfolio Balance: Advancing both high-prevalence indications and rare diseases with strong regulatory incentives.
Conclusion
In silico Medicine’s 2025 milestones mark a defining moment for AI in drug development. With proof-of-concept clinical data, regulatory recognition, and a pipeline designed with precision from the start, the company is reshaping expectations for how quickly and effectively new therapies can be brought to patients. The coming 12–18 months will reveal whether these AI-born candidates can deliver on their clinical promise. If they do, the conversation in pharma may permanently shift—from asking if AI can make drugs to planning how fast it can bring them to market.
Learn More
Explore Empower School of Health’s Post Graduate Diploma in Pharmaceutical Management, a comprehensive 12-month online program recognized by UNITAR and FIP. Gain in-depth knowledge of medicine regulation, pharmaceutical marketing, health supply chain, and medicine policies, along with a pharmacoinformatics module that includes dedicated topics on AI in drug discovery and development to excel in the evolving pharmaceutical landscape.
References
- 1. Genetic Engineering & Biotechnology News (2025) Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate. Genetic Engineering & Biotechnology News.
- 2. PR Newswire (2025) Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach. PR Newswire.
- 3. PR Newswire (2025) Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease. PR Newswire.
- 4. CityBiz (2025) Insilico Medicine Announces First Patient Dosed in Phase I Clinical Trial of ISM6331, the Novel Inhibitor for the Treatment of Mesothelioma and other Solid Tumors. CityBiz.
- 5. EurekAlert! (2025) Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors. EurekAlert!.
- 6. Drug Target Review (2025) First AI-designed drug, Rentosertib, officially named by USAN. Drug Target Review.
- 7. Mesothelioma Hope (2025) First ISM6331 Dose Given to Mesothelioma Patient in Clinical Trial. Mesothelioma Hope.
- 8. Insilico Medicine (2025) A Phase 2 Readout Generates Excitement for the Potential of AI-Driven Drug Discovery. Insilico Medicine Blog.
- 9. U.S. National Library of Medicine (2025) Study of ISM5939 in patients with advanced and/or metastatic solid tumors. ClinicalTrials.gov.